Board of directors

Fimbrion Therapeutics, Inc. is a life sciences company based in St. Louis, MO founded in 2012 from intellectual property licensed from Washington University. Fimbrion’s mission is to discover, develop, and commercialize antimicrobial-sparing, first-in-class antivirulence drugs for the prevention and treatment of infectious diseases caused by bacteria, including antibiotic-resistant strains.

 
 
hultgren.jpg

Scott J. Hultgren, PhD, Co-Founder
Professor of Molecular Microbiology and Director, Center for Women's Infectious Disease Research, Washington University School of Medicine

  • 297 Publications in Biological, Biochemical and Biophysical Sciences, as well as Infectious Diseases, Chemistry, and Drug Design

  • Member of the National Academy of Sciences

  • Member of the National Academy of Medicine

  • Fellow of the National Academy of Inventors

  • 15 US Granted Patents Including the Mannoside Technology

  • Nobel Fellow, Luminary and 2nd Century Award Winner

 
janetka350.jpg

James W. Janetka, PhD, Co-Founder
Professor of Biochemistry & Molecular Biophysics
Adjunct Professor of Chemistry, Washington University School of Medicine

  • Accomplished Medicinal Chemist with Drug Discovery and Development Experience at Vertex and AstraZeneca

  • 60+ Publications in Synthetic Organic and Medicinal Chemistry, Biochemistry, Oncology, and Infectious Diseases

  • 26 US Granted Patents Including the Mannoside Technology

  • Five clinical candidate drugs: BVD-523 (Ulixertinib), AZD7762, AZD8542, AZD7254 and GSK3882347 (Mannoside)

 
_MG_3714-2.jpg

Thomas M. Hooton, MD, Co-Founder
Chief of Medicine (Retired 2020), Miami VA Healthcare System, Voluntary Professor of Clinical Medicine, University of Miami Miller School of Medicine

  • 150 Peer-Reviewed Publications in UTI, STI, Antimicrobial Stewardship, and other areas of Infectious Diseases

  • Author or Co-Author on IDSA Practice Guidelines for Catheter-Associated UTI, Uncomplicated Cystitis, Asymptomatic Bacteriuria, and Antimicrobial Stewardship

  • Author or Co-Author on UTI Chapters in Online Text UpToDate

  • Key Opinion Leader on UTI

 

Christina L. Stallings, PhD
Professor of Molecular Microbiology, Center for Women’s Infectious Disease Research, and Director of the Molecular Microbiology and Microbial Pathogenesis Graduate Program, Washington University School of Medicine

  • 51 Publications in Infectious Disease

  • 3 Patents including inhibitors of Mycobacterium tuberculosis QcrB

  • Burroughs Wellcome Fund Investigator in the Pathogenesis of Infectious Disease